Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma
Clinical trial NCT03352947 · COMPLETED
Trial details
- NCT number
- NCT03352947
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-03
- Primary completion
- 2020-03-31
- Enrollment
- 79
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.